Sarcopenia in patients with advanced liver disease

Francesca Romana Ponziani, Antonio Gasbarrini

Research output: Contribution to journalReview article

Abstract

© 2018 Bentham Science Publishers. Sarcopenia is the loss of muscle mass and function, affecting up to 70% of patients with advanced liver disease. Liver cirrhosis is characterized by an altered glucose metabolism, lipid oxidation, ketogenesis and protein catabolism, leading to the loss of adipose and muscle tissue. The gastrointestinal dysfunction of cirrhotic patients results in inadequate nutrients intake and is responsible for muscle weakness thus limiting physical exercise and perpetuating the reduction of muscle mass. Recently, alterations of hormonal pathways involved in muscle growth, increased intestinal permeability and changes in the gut microbiota composition have been reported in cirrhotic patients. Interestingly, a role of intestinal bacteria in maintaining muscle health has been hypothesized through the translocation of bacteria and bacterial products into the bloodstream triggering the production of muscle wasting-related cytokines. Sarcopenia is associated with severe outcomes in patients with liver cirrhosis, mostly due to the incidence of disease complications. Furthermore, sarcopenia may represent an important prognostic factor for patients with hepatocellular carcinoma and for those undergoing liver transplantation and can be considered a useful additional tool in the global assessment of patients with advanced liver disease.
Original languageEnglish
Pages (from-to)681-691
Number of pages11
JournalCurrent Protein and Peptide Science
Volume19
Issue number7
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Sarcopenia
Liver
Muscle
Liver Diseases
Muscles
Liver Cirrhosis
Bacteria
Bacterial Translocation
Muscle Weakness
Lipid Metabolism
Liver Transplantation
Adipose Tissue
Hepatocellular Carcinoma
Permeability
Nutrients
Exercise
Cytokines
Glucose
Food
Health

Keywords

  • Gut microbiota
  • Intestinal permeability
  • Liver cirrhosis
  • Liver disease
  • Liver transplantation
  • Malnutrition
  • Sarcopenia

Cite this

Sarcopenia in patients with advanced liver disease. / Ponziani, Francesca Romana; Gasbarrini, Antonio.

In: Current Protein and Peptide Science, Vol. 19, No. 7, 01.01.2018, p. 681-691.

Research output: Contribution to journalReview article

Ponziani, Francesca Romana ; Gasbarrini, Antonio. / Sarcopenia in patients with advanced liver disease. In: Current Protein and Peptide Science. 2018 ; Vol. 19, No. 7. pp. 681-691.
@article{06ad771250254e7b9a38e4a96a525f9a,
title = "Sarcopenia in patients with advanced liver disease",
abstract = "{\circledC} 2018 Bentham Science Publishers. Sarcopenia is the loss of muscle mass and function, affecting up to 70{\%} of patients with advanced liver disease. Liver cirrhosis is characterized by an altered glucose metabolism, lipid oxidation, ketogenesis and protein catabolism, leading to the loss of adipose and muscle tissue. The gastrointestinal dysfunction of cirrhotic patients results in inadequate nutrients intake and is responsible for muscle weakness thus limiting physical exercise and perpetuating the reduction of muscle mass. Recently, alterations of hormonal pathways involved in muscle growth, increased intestinal permeability and changes in the gut microbiota composition have been reported in cirrhotic patients. Interestingly, a role of intestinal bacteria in maintaining muscle health has been hypothesized through the translocation of bacteria and bacterial products into the bloodstream triggering the production of muscle wasting-related cytokines. Sarcopenia is associated with severe outcomes in patients with liver cirrhosis, mostly due to the incidence of disease complications. Furthermore, sarcopenia may represent an important prognostic factor for patients with hepatocellular carcinoma and for those undergoing liver transplantation and can be considered a useful additional tool in the global assessment of patients with advanced liver disease.",
keywords = "Gut microbiota, Intestinal permeability, Liver cirrhosis, Liver disease, Liver transplantation, Malnutrition, Sarcopenia",
author = "Ponziani, {Francesca Romana} and Antonio Gasbarrini",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1389203718666170428121647",
language = "English",
volume = "19",
pages = "681--691",
journal = "Current Protein and Peptide Science",
issn = "1389-2037",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - Sarcopenia in patients with advanced liver disease

AU - Ponziani, Francesca Romana

AU - Gasbarrini, Antonio

PY - 2018/1/1

Y1 - 2018/1/1

N2 - © 2018 Bentham Science Publishers. Sarcopenia is the loss of muscle mass and function, affecting up to 70% of patients with advanced liver disease. Liver cirrhosis is characterized by an altered glucose metabolism, lipid oxidation, ketogenesis and protein catabolism, leading to the loss of adipose and muscle tissue. The gastrointestinal dysfunction of cirrhotic patients results in inadequate nutrients intake and is responsible for muscle weakness thus limiting physical exercise and perpetuating the reduction of muscle mass. Recently, alterations of hormonal pathways involved in muscle growth, increased intestinal permeability and changes in the gut microbiota composition have been reported in cirrhotic patients. Interestingly, a role of intestinal bacteria in maintaining muscle health has been hypothesized through the translocation of bacteria and bacterial products into the bloodstream triggering the production of muscle wasting-related cytokines. Sarcopenia is associated with severe outcomes in patients with liver cirrhosis, mostly due to the incidence of disease complications. Furthermore, sarcopenia may represent an important prognostic factor for patients with hepatocellular carcinoma and for those undergoing liver transplantation and can be considered a useful additional tool in the global assessment of patients with advanced liver disease.

AB - © 2018 Bentham Science Publishers. Sarcopenia is the loss of muscle mass and function, affecting up to 70% of patients with advanced liver disease. Liver cirrhosis is characterized by an altered glucose metabolism, lipid oxidation, ketogenesis and protein catabolism, leading to the loss of adipose and muscle tissue. The gastrointestinal dysfunction of cirrhotic patients results in inadequate nutrients intake and is responsible for muscle weakness thus limiting physical exercise and perpetuating the reduction of muscle mass. Recently, alterations of hormonal pathways involved in muscle growth, increased intestinal permeability and changes in the gut microbiota composition have been reported in cirrhotic patients. Interestingly, a role of intestinal bacteria in maintaining muscle health has been hypothesized through the translocation of bacteria and bacterial products into the bloodstream triggering the production of muscle wasting-related cytokines. Sarcopenia is associated with severe outcomes in patients with liver cirrhosis, mostly due to the incidence of disease complications. Furthermore, sarcopenia may represent an important prognostic factor for patients with hepatocellular carcinoma and for those undergoing liver transplantation and can be considered a useful additional tool in the global assessment of patients with advanced liver disease.

KW - Gut microbiota

KW - Intestinal permeability

KW - Liver cirrhosis

KW - Liver disease

KW - Liver transplantation

KW - Malnutrition

KW - Sarcopenia

UR - http://www.scopus.com/inward/record.url?scp=85048888245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048888245&partnerID=8YFLogxK

U2 - 10.2174/1389203718666170428121647

DO - 10.2174/1389203718666170428121647

M3 - Review article

AN - SCOPUS:85048888245

VL - 19

SP - 681

EP - 691

JO - Current Protein and Peptide Science

JF - Current Protein and Peptide Science

SN - 1389-2037

IS - 7

ER -